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Mitochondrial diseaseMitochondrial DNA mutations are well recognized as an important cause of disease, with over two hundred
variants in the protein encoding and mt-tRNA genes associated with human disorders. In contrast, the two
genes encoding the mitochondrial rRNAs (mt-rRNAs) have been studied in far less detail. This is because
establishing the pathogenicity of mt-rRNA mutations is a major diagnostic challenge. Only two disease causing
mutations have been identified at these loci, both mapping to the small subunit (SSU). On the large subunit
(LSU), however, the evidence for the presence of pathogenic LSU mt-rRNA changes is particularly sparse. We
have previously expanded the list of deleterious SSU mt-rRNA mutations by identifying highly disruptive base
changes capable of blocking the activity of the mitoribosomal SSU. To do this, we used a new methodology
named heterologous inferential analysis (HIA). The recent arrival of near-atomic-resolution structures of the
human mitoribosomal LSU, has enhanced the power of our approach by permitting the analysis of the corre-
sponding sites of mutation within their natural structural context. Here, we have used these tools to determine
whether LSUmt-rRNAmutations found in the context of human disease and/or ageing could disrupt the function
of themitoribosomal LSU. Our results clearly show that,much like the for SSUmt-rRNA, LSUmt-rRNAsmutations
capable of compromising the function of themitoribosomal LSU are indeed present in clinical samples. Thus, our
work constitutes an important contribution to an emerging viewof themitoribosome as an important element in
human health.
© 2015 The Authors. Elsevier B.V. andMitochondria Research Society. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Mitochondria are the cellular powerhouses and contain a small
circular chromosome (mtDNA). Human mtDNA codes for 13 essential
polypeptide components of the mitochondrial oxidative phosphoryla-
tion chain, which generates most of the cells' ATP. More than 250
pathogenic mutations and large-scale re-arrangements of the mito-
chondrial chromosome have been identified, as causative of a heteroge-
neous group of diseases. Most pathogenic mutations are present as
heteroplasmic variants, meaning that both wild-type and mutatedjo).
ondria Research Society. This is an opmtDNA co-exist within the cells of patients. The precise threshold
level of mutant mtDNA required for a major biochemical defect within
the cell depends on the mutation, and shows variation with tissue
type and between individual patients. This results in a complex and
heterogeneous pattern of disease presentation (Tuppen et al., 1797).
Indeed the penetrance of mtDNA mutations is highly variable, and
known to be influenced by a number of factors. It has been estimated
that the minimal prevalence of mtDNA disease in adults is 1 in 4300
in the UK (Gorman et al., 2015). As such, mtDNA mutations must be
considered an important cause of inherited disease. In addition, the
high mutation rate of mtDNA within cells and its continuous turnover
independent of cell cycle, results in the accumulation of somatic
mutations with time (Wallace, 2010; Elson et al., 2001). For this reason,
the detection of somatic mtDNA mutations in aged and cancerous
tissues is amply documented in the literature.en access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of components of the machinery required to synthesise these polypep-
tides, namely 2 ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs)
(Scheffler, 1999). Mt-rRNA genes encode the RNA component of mito-
chondrial ribosomes or mitoribosomes. The mammalian mitoribosome
consists of a 28S small subunit (mt-SSU), where genetic decoding
occurs, and a 39S large subunit (mt-LSU), which holds the peptidyl
transferase activity (Koc et al., 2010). Given the central role of the
mitoribosome in mitochondrial gene expression, it is not surprising
that some mt-rRNAmutations have emerged as causative of mitochon-
drial disease. Our understanding of the role, diagnosis and transmission
of mutations in the mtDNA protein encoding genes and mt-tRNA genes
has improved greatly over the last 10 years, at least in European
populations (Mitchell et al., 2006; Yarham et al., 2011; Stewart et al.,
2008; Elson et al., 2009). However, much less is known about disease
causing mutations in the mt-rRNA genes than in any of the other
genes of mtDNA. Thus, efforts to expand our knowledge of the impor-
tance of mt-rRNA variation in disease may be considered one of the
last frontiers in the understanding of the role of mtDNA mutations in
human disease.
The intractability of the mitochondrial translation apparatus,
together with the lack of methods for the manipulation of mtDNA
makes it impossible to biochemically and genetically test the effect of
these mutations directly. As such, it is not surprising that to date, only
two mt-rRNA mutations exist for which direct biochemical evidence
has clearly established a role in the onset mtDNA disease (Bindu and
Reddy, 2008; Smith et al., 2014). In an attempt to identify more mt-
rRNA mutations capable of interfering with mitoribosomal function,
we have described a method named HIA, which we used to assess the
disruptive potential of mt-rRNA variations in the mt-small ribosomal
subunit (mt-SSU) (Smith et al., 2014; Elson et al., 2015). The method
is based on the striking evolutionary conservation of the overall fold of
rRNAs, which attests to both the common ancestry of these molecules
and their pivotal biological role (Cannone et al., 2002). HIA combines
conservational informationwith functional and structural data obtained
from heterologous ribosomal sources, and can be used to make predic-
tions of the disruptive power of mt-rRNA variants (Smith et al., 2014).
We have successfully usedHIA to reveal the pathogenic character of cer-
tain mt-rRNA mutations in the mt-SSU for which the available genetic
and pathological evidence was unambiguous (Smith et al., 2014). Nota-
bly, a structure-based method similar to ours have recently been ap-
plied to predict the disruptive potential of mtDNA mutations within
protein-coding genes (Lloyd and McGeehan, 2013).
Recent advances in cryo-EM technology have allowed the
achievement of medium- and near-atomic-resolution structures of
mitochondrial ribosomal particles, including a 3.4 Å-resolution struc-
ture of the Homo sapiens large subunit (mt-LSU) (Brown et al., 2014).
The availability of this structure is a major step towards achieving a
better understanding of the role of mt-rRNA mutations in human
disease. In addition to facilitating direct location of sites of variation on
the correct structure, it has allowed the advancement of our HIA
analysis to assess the functional and/or structural role of such sites.
Here, we use these tools to analyse the effects of LSU mt-rRNA
mutations on the function of the large mitoribosomal subunit.
2. Methods
A detailed description of the HIA methodology has been recently
published (Smith et al., 2014; Elson et al., 2015). Aspects of particular
importance to this work are described below.
2.1. Sources of mutational data
The following sources of mutational data were used in this study:
(a) scientific literature, (b) MITOMAP list of unpublished variants
(Ruiz-Pesini et al., 2007), and (c) our own unpublished material. Asfor our previous work on the small mitoribosomal rRNA (Smith et al.,
2014), the criterion required for mt-rRNA mutations to be included in
this study was their identification in human subjects, with either a
suspected mitochondrial disease or somatic mtDNA mutations that
had undergone clonal expansions in cancer patients, or COX-deficient
cells located in aged tissues. In the case of studies involving
tumourigenic tissue, the existence of non-cancerous control tissue
from the same patient was a requirement. Similarly, the existence of
COX-proficient surrounding tissue was a requirement in the case of
COX-deficient samples of aged individuals. This allowed the variant to
be identified as a somatic mutation that had undergone clonal
expansion.
2.2. Analysis of GenBank mitochondrial genome data
We have previously described our strategy to filter out mutations
with appearances in samples obtained from normal individuals
(Smith et al., 2014; Elson et al., 2015). As of the end of 2013, there
existed 21,591 human mtDNA sequences in GenBank (query =
‘Homo[Organism] + AND+ gene_in_mitochondrion[PROP] + AND +
14,000:19,000[SLEN] + NOT + pseudogene[All Fields]’ (Pereira et al.,
2009)). All sequences were downloaded with Entrez Programming
Utilities and our own PERL scripts (Sayers, 2010). The data was
downloaded in FASTA format and sequentially aligned to the Cambridge
Reference (NC_012920.1) (Andrews et al., 1999) by means of the
MAFFT package (Katoh et al., 2002), which provided a quick algorithm
for massive sequence alignment. The generated alignments were then
analysed by means of a PERL script that recorded the total number of
appearances for every variation. For variations with 15 or less appear-
ances in the combined dataset, including the data from both the
GenBank and Phylotree databases, the possibility that the individual
sequences could be linked to mitochondrial disease was investigated,
by inspecting the related publication sources. In all cases it was
observed that no new patient sequences, other than the ones previously
found in the literature, were present within GenBank.
In addition to this strategy, here we have also used the tools
available within the MITOMAP database (Ruiz-Pesini et al., 2007).
Only mutations passing these filters, were analysed in this work
(Supplementary Table 1).
2.3. Structural inspection
The improved version of the HIA method used here includes the
following changes. The availability of a 3.4 Å-resolution structure of
the H. sapiens mt-LSU (Brown et al., 2014), has prompted us to use
this structure to directly place the sites of variation under analysis
(RCSB accession code: 3J7Y). Direct structural analysis on structure
3J7Y was complemented with comparisons to superimposed structures
representative of all three kingdoms of life and mitochondria. In the
bacterial case, the availability of structures in different steps of the
translation cycle was also exploited. The structures used in this analysis
are described in Supplementary Table 2. The quality of 3J7Y's RNA
density was visually evaluated prior to HIA analysis.
Tertiary and quaternary interactions are visually assignedwith UCSF
Chimera (Pettersen et al., 2004) on superimposed high-resolution
structures of LSUs belonging to bacterial (Thermus thermophilus and
Escherichia coli), eukaryotic, archaeal, and mitochondrial (including
human and yeastmitochondria) phylogenetic domains (Supplementary
Table 2). Superimpositions were performed as described (Elson et al.,
2015).
To show the positions of A- and P-site tRNAs in Fig. 2, the following
superimposition strategy was followed. RCSB ID 2WDK, containing the
3.5 Å structure of the T. thermophilus SSU plus all three tRNAs, was
superimposed onto 2J00, a higher resolution structure from the same
organism (2.8 Å, Supplementary Table 2) (Voorhees et al., 2009;
Selmer et al., 2006). The RMSD between 1476 atom pairs was 0.700 Å
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mitoribosomal LSU structure was superimposed onto 2J01, the LSU of
2J00 (Supplementary Table 2), with an RMSD of 0955 Å between
410 atom pairs (Brown et al., 2014; Selmer et al., 2006). For the
mitochondrial SSU, the 7.0 Å Bos taurus structure (RCSB ID: 3J6V) was
superimposed onto 2J00 (Kaushal et al., 2014), with an RMSD of
1.452 Å between 83 atom pairs.2.4. Disruptive power assessment
As highlighted in our previous studies (Smith et al., 2014), the
disruptive potential was estimated as follows: N = ‘certainly not
disruptive’, supportive direct heterologous mutagenesis data in favour
of this assignment exists for the tested residue or its base-pairing part-
ner, U = ‘unlikely disruptive’, no direct heterologous mutagenesis data
exist but enough indirect data exist in favour of this conclusion; NEE=
‘not enough evidence’, no direct or indirect evidence argues against a
potential disruptive power; L = ‘likely disruptive’, no direct heterolo-
gous mutagenesis data exist but enough indirect data exist in favour
of this conclusion and E= ‘expectedly disruptive’, supportive direct het-
erologous mutagenesis data exist for the tested residue or its base-
pairing partner. Two additional categories were used to classify the
mitochondrial mutations: und = ‘undetermined’, no heterologous
data exist to evaluate the disruptive potential or the existing structural
differences are too large to allow the extrapolation of conclusions
made in the heterologous case and P='proven', direct biochemical
evidence exists to support a disruptive role.Fig. 1. Secondary structure of the human LSUmt-rRNA. Modified from Brown et al. (2014). rRN
box. Sites of variation are colour coded as follows: Red, “unlikely”; yellow, “undetermined”; gre
erences to color in this figure legend, the reader is referred to the web version of this article.)3. Nomenclature
Conserved interactions are indicated in themain text as a C followed
by the corresponding beamM, for observed interactions in the bacterial,
eukaryotic, archaeal, mammalian mitochondrial, and yeast mitochon-
drial ribosomes. In the absence of the corresponding symbol, a plus
sign (+) indicates that all the partners for a potential interaction are
present in a particular organism, but the interaction has not been
modelled in the published structure, a minus (−) sign denotes that
one of the partners in an interaction is absent in a particular organism,
and a question mark (?) indicates that the interaction is not observed
in a particular organism despite the fact that potential partners for it
are present. For the description of the higher-order structure of the
mt-LSU, mitochondrial numbering (regular font) refers to H. sapiens.
E. coli numbering is the accepted standard for rRNA, therefore it is
used here to denote bacterial rRNA residues (italicised). Conservation
indexes, Cvs, calculated as described by Cannone et al. (2002), are also
provided. All human sites of variation tested here, aswell as their heter-
ologous equivalents will be underlined. Atom-to-atom distances below
3 Å are reported.
4. Results
We have analysed 145 potentially disruptive mutations mapping
to the human 16S mt-rRNA. Among these mutations, we identified
64 variants with no appearances in GenBank, other than the ones
originating from the sources reporting them as potentially pathogenic
(Supplementary Table 1). Fig. 1 shows the sites of these mutationsA domains are indicated by large Roman numerals. Helix 32 is indicated with solid yellow
y, “NEE”; cyan, “likely”; blue, “expectedly”; black, “proven”. (For interpretation of the ref-
Table 1
Classification of mt-LSU rRNAmutations according to their predicted disruptive potential on
ribosomal function.
The table includes all mitochondrial mutations meeting the criteria described in Methods.
Variation Canonical
base pair
partner
(H. sapiens)
Bacterial
equivalent
Canonical
base pair
partner
(bacterial)
Tunnel
NEE
122G N A m.1792G N A 115C G468 C461 Y
161G N A m.1831G N A 169C C535 G558
216G N A m.1886G N A U606
222A N G m.1892A N G
235C N A m.C1905C N A C673 Y
243G N A m.1913G N A 336C G681 C796 Y
270A N G m.1940A N G 264U C730 G702
282U N C m.T1952T N C 295A G742 C755
297U N C m.1967T N C 280U U757 U740
320G N A m.1990G N A G780 Y
334G N A m.2004G N A 245C 794 683 Y
337U N C m.2007T N C 242A C797 G680 Y
345G N A m.2015G N A G805 Y
404delA m.2074delA
409C N U m.2079C N T
413U N G m.2083T N G
449 3T N 4T m.2119 3T N 4T 432A U967 G950
451G N A m.2121G N A 430C G969 C948
478–479
dupAG
m.2148–2149
dupAG
582C &
583U
G997 &
C998
G1157 &
C1158
480 delU m.2150 delT ? U999 A1155
481 delA m.2151 delA A1000
605U N C m.2275T N C 620A U1199 A1246
880A N U m.2550A N T G1839
948U N C m.2618T N C U1955
973G N C m.2643G N C A1980 C1771
974A N G m.2644A N G A1981
994U N C m.2664T N C 793A C2001 G1659
1028G N A m.2698G N A G2035 Y
1135A N U m.2805A N T 1072U A2241 U2079
1283U N C m.2953T N C 1301A C2466 G2484
1328 InsU m.2998 InsT U2511
1344G N A m.3014G N A 1353C C2527 G2536
1362G N A m.3032G N A 1337C G2545 C2520
1384G N A m.3054G N A 1334C G2567 C2517
1490A N U m.3160A N T
1535C N U m.3205C N T
Unlikely
34U N C m.1704T N C
253C N U m.1923C N T 311G C691 G771
568A N G m.2238A N G
677C N U m.2347C N T 696G
1011G N A m.2681G N A 157C G2018 C531
1433C N U m.3103C N U 1046G C2616 G2053
Undetermined
399U N G m.2069T N G
551C N U m.2221C N T
1114A N C m.2784A N C
1120 InsT m.2790 InsT
1214C N U m.2884C N T
Likely
629U N A m.2299T N A U1255
875U N C m.2545T N C U1834
889U N G m.2559T N G
923G N A m.2593G N A G1930
1169C N A m.2839C N A 1149G C2275 G2255
1253G N A m.2923G N A 1066C G2436 C2073
1328U N C m.2998T N C U2511
1409G N A m.3079G N A 1418C G2592 C2601
1412G N C m.3082G N C G2595
1420G N A m.3090G N A 1408C G2603 C2591
1423C N G m.3093C N G 1405G C2606 G2588
1424G N A m.3094G N A G2607
Expectedly
1010U N C m.2680T N C 636A U2017 A1262 Y
1145G N A m.2815G N A G2251
1146G N A m.2816G N A G2252
1398G N A m.3068G N A G2581
Proven
173U N C m.1843T N C 1026A U562 A2033
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HIA analysis resulted in: 6 variants whose disruptive potential on the
function of mitoribosomes was considered to be “unlikely disruptive”,
and 5 which cannot be placed on the high-resolution human cryo-EM
structure of the mt-LSU (undetermined) (Brown et al., 2014). An
additional 36 variants were regarded as not having enough evidence
“NEE”, 12 variants were deemed “likely disruptive”, 4 were considered
“expectedly disruptive”, and 1 mutation was confirmed as “proven”
(Table 1). What follows is an analysis of the relevant conclusions from
the point of view of mitochondrial function and human disease, for
mutations within the “likely”, “expectedly”, and “proven” categories.
5. Domain I mutations
A potentially pathogenic mutation was identified in a respiratory
chain-deficient cybrid cell line by Seibel et al. at position 173U
(m.1843T N C) (Seibel et al., 2008). Residue 173U lies between helices
H25a andH25b and is part of a triple base interaction involving residues
of helix H72 (Figs. 1 and 2A). This interaction, which contributes to
bringing together domains I and V of the LSU rRNA, is established via a
Watson:Crick base pair between 173U and 1026A (m.2696A), and a
reverse Hoogsteen between 1026A and 1021U (m.2691U) of H72
(bacterial: U562:A2033·U2028; Cv(U562) = 0.992, Cv(A2033) = 1.292,
Cv(U2028) = 1.197)CbeamM. The 173U N C transition is likely to disrupt
the triple base interaction even if a C·A+ wobble could be formed be-
tween the mutated 173C and 1026A. This is because the protonation
of the N1 of 1026A would disrupt the reverse Hoogsteen configuration
(Pan et al., 1998; Saenger, 1984). The loss of base pairing interactions
in the neighbourhood of this triple base interaction was demonstrated
to be highly detrimental to ribosomal function bymutagenesis in bacte-
ria (specifically, residues 2025 and 2026) (O'Connor, 2007; Thompson
et al., 2001a). Notably, mutations at the adjacent G2032 of the bacterial
ribosome are known to cause resistance to the oxazolidinone antibiotic
linezolid (Kloss et al., 2000). Interestingly, functional analysis of cybrid
cell lines carrying this mutation in addition to the NEE variant
270A ≥ G (m.1940A N G), showed a dramatic reduction in the amount
of mitochondrially encoded proteins (Seibel et al., 2008). It is likely
that the observed deleterious effects can be mostly attributed to the
173U N C (m.1843T N C) mutation, as the NEE variant 270A N G
(m.1940A N G) is not expected to cause major structural defects,
(Table 1). Given this evidence, the 173U ≥ C (m.1843T N C) mutation
is classified as a “proven disruptive” mutation.
6. Peptide exit tunnel (ET)
Two interesting disruptivemutationsmap to the PET. This structural
element spans the distance from the peptidyl transferase centre (PTC)
to the peptide exit site on the opposite end of the large subunit
(Pechmann et al., 2013). The folding of nascent peptide chains starts
within the PET, where they can even form helices (Pechmann et al.,
2013). In mammalian mitochondria, the tunnel appears to be adapted
for the translation of hydrophobic membrane proteins (Brown et al.,
2014).
A U N C heteroplasmic variant was identified at position 1010
(m.2680) in a breast cancer tumour sample (Gochhait et al., 2008).
Note that the assignment of a C N U at this position in the original report
was a typographical error (personal communication from Dr. Bamezai).
In the human cryo-EM structure, 1010U forms aWatson–Crick base pair
with 636A (bacterial: A1262:U2017; Cv(A1262) = 0.525 and Cv(U2017) =
0.638), a residue flanking one of the ends of helix H26 on the wall of
the peptide exit tunnel (Figs. 1 and 2B). Base changes disrupting the
bacterial equivalent of this base pair have been shown to be highly
detrimental for ribosome function (Aagaard and Douthwaite, 1994).
While it is possible that the U N C base change at position 1010
(m.2680) might result in an A+·Cwobble, the bacterial studies showed
that the wobble configuration at this site was not sufficient to fully
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evidence prompts us to regard the U N C heteroplasmic variation at
m.2680 as “expectedly disruptive”.
The opposite end of helix H26 in the human mitoribosome also
harbours the potentially pathogenic mutation 629U N A (m.2299T N A).
This variant was identified in a sample from a patient with colorectal
cancer by Polyak et al. (1998). In the human mitochondrial structure
629U (bacterial U1255; Cv(U1255) = 1.848) is stacked upon a loop of
protein MRPL4 whose primary sequence is highly conserved between
bacteria and mitochondria (Figs. 1 and 2B; an alignment between
MRPL4 and the bacterial L4 is provided as Supplementary material).
The loop forms part of the lining of the peptide exit tunnel, and in bacte-
ria it is known to harbourmutations that confer erythromycin-resistance
(Zaman et al., 2007). A contact between the ribose of 629U and the
phosphate oxygen of 189A of helix H25bCbeam (bacterial: A578;
Cv(A578) = 0.884) is also observed (Fig. 2B). The high conservation of
629U, together with its involvement in long-range interactions suggests
an important role for this residue. In agreement with this hypothesis, is
the observation in bacteria that mutations of neighbouring residues of
protein L4 produce slow growing phenotypes (Zaman et al., 2007).
Thus, we regard 629U N A (m.2299T N A) as a “likely disruptive”
mutation.
7. Domain IV bridges and associated regions
Domain IV of the bacterial LSU is involved in the formation of several
inter-subunit bridges that link the two ribosomal subunits. This region
of the ribosome has been implicated in numerous ribosomal functions
including subunit association, tRNA binding, initiation, translocation,
translational accuracy, peptidyl transferase reaction, and ribosome
recycling (Ali et al., 2006).
7.1. Bridges B2b and B2c
The importance of these bridges in subunit association has been
clearly demonstrated (Ghosh and Joseph, 2005; Rackham et al., 2006).
On the LSU, bridges B2b and B2c involve residues of helices H67, H69,
and H71, and of helix H67 respectively (Fig. 1) (Yusupov et al., 2001).
We will examine three mutations that lie in close proximity of these
bridges.
Linking helices H67 and H68 is the almost invariant residue 875U
(bacterial: U1834; Cv(U1834) = 1.913) (Figs. 1 and 2C), where a C N U
mutation has been identified in a sample from a patient with prostate
cancer (Kloss-Brandstatter et al., 2010). Position 875U lies in the
neighbourhood of another highly conserved site of mutation, namely
923G (m.2593G) (H. sapiens: 923G; bacterial: G1930; Cv(G1930) =
1.963) (Figs. 1 and 2C), where a G N A base change has been identified
in a COX-deficient gastric unit (McDonald et al., 2008).
The high degree of conservation of positions 875U (m.2545T) and
923G (m.2593G) is likely to be explained by their probable role in
local structure stabilization, in particular the clamping of the sharp
bend between residues 961 and 966 (grey face in H sapiens, and E. coli
figure) (bacterial: 1968 and 1973; Cv(average) = 1.683) (Fig. 2C). The
N3 of 875U is within hydrogen-bond distance of the N7 of 963ACbeamM
(bacterial: U1834·A1970; Cv(U1834) = 1.913, Cv(A1970) = 1.881) at the
very apex of the sharp bend. This interaction is continued via a contact
between the N3 of 963A and the 2'OH of 868C (bacterial: C1827;
Cv(C1827) = 1.383)CbeamM that connects the bend to helix H66. This
continuous hydrogen-bonding network reaches even further due to
the formation of a C·A+ wobble between 868C and 842A (bacterial:
G1792; Cv(G1792) = 1.116).
The case of 923G is similar to that of 875U. TheWatson–Crick face of
923 is modelled to be within less than 3 Å of the RNA backbone at
position 962ACbeamM (bacterial: A1969; Cv(A1969) = 1.952) (Fig. 2C),
while its ribose 2'OH makes a contact with 961's baseCbeamM of thehighly conserved 925A·961G sheared base pair (H. sapiens: 925A·961G;
bacterial: A1932·G1968, Cv(A1932)= 1.947; Cv(G1968) = 1.852)CbeamM.
Regarding the possible effects of the 875U N C (m.2545T N C) and
923G N A (m.2593G N A)mutants, themitochondrial structure indicates
that the U N C substitution at position 875would result in the loss of the
N3–N7 hydrogen bond with 963A. Similarly, the G N A base change at
position 923 would also result in the loss of one hydrogen bond. Given
the high conservation of the residues in this region, their involvement
in maintenance of local structure, and the proximity to bridges B2b
and B2c; it appears logical to propose that such losses of hydrogen-
bonding potential in this region should be deleterious. Mutagenesis of
some adjacent bridge residues that has been performed in bacteria
corroborates this idea (Liiv andO'Connor, 2006). For example, mutation
of residues neighbouring B2b resulted in biochemical and growth
defects, including some recessive lethal phenotypes. However, it was
also shown that B2c bridgemutants thatmaintained base pairing across
helix H67 result in relatively minor growth and subunit association
defects, whereas mutations that did not maintain base pairing across
helix H67 led to phenotypes of greater severity (Liiv and O'Connor,
2006). Furthermore, lack of methylation at position G1835 in bacteria
(H. sapiens: 876A; Cv(G1835) = 1.861) has been shown to cause impor-
tant growth defects under osmotic and oxidative stress, situations that
might be relevant to mitochondrial translation (Osterman et al.,
2011). Finally, deleterious mutations have also been found on the SSU
side of the bridge in bacteria (Ghosh and Joseph, 2005; Rackham et al.,
2006; Kim et al., 2007; Belanger et al., 2004) and we have previously
identified two “likely disruptive” variants in the 12S mt-rRNA compo-
nent of bridge mt-B2c (Smith et al., 2014). In summary, the data
presented here is consistent with a “likely disruptive” potential for the
two LSU mutations located on bridge mt-B2c, namely 875U N C
(m.2545T N C) and the 923G N A (m.2593G N A). In the case of the
875U N C (m.2545T N C), a second LSU somatic mutation has been
observed in the same sample (Supplementary Table 1), mapping to
position 337U (m.2007T) within the PET (Kloss-Brandstatter et al.,
2010). As the two sites of mutation are far apart in the LSU structure
and we assigned a “NEE” score to 337U (m.2007T) (Table 1), the possi-
bility of a synergistic, disruptive effect of the two base changes cannot
be ruled out.
7.2. Bridge B7a
Superposition of the recent cryo-EM structures of the bacterial and
mammalian mitoribosomal subunits shows that the surface area
involved in bridge B7a is smaller in the mammalian mitoribosome
than in its bacterial counterpart, due to the shorter length of helix H68
in the former (Brown et al., 2014; Kaushal et al., 2014; Greber et al.,
2014).
The 889U N G (m.2559T N G) variant was identified in a COX-
deficient colonocyte at levels of 50% heteroplasmy (Greaves et al.,
2010). In the human mitochondrial structure 889U forms a Watson–
Crick base pair with 886A (m.2556A) within H68's capping loop
(Figs. 1 and 2D). The available structural data places position 889A at
the very centre of the mitochondrial bridge, i.e. a distance of less than
4 Å can be measured between the phosphate oxygen of 889A and the
RNA backbone of the superimposed B. taurus 7.0 Å cryo-EM structure
(Fig. 2D) (Brown et al., 2014; Kaushal et al., 2014).
While caution should be used when interpreting the aforemen-
tioned structural details, given the low resolution of the B. taurus
structure, the location of the 889U N G (m.2559T N G) prompts us to
consider its disruptive potential as “likely disruptive”.
7.3. Ribosomal peptidyl transferase centre (PTC)
The PTC is one of the essential functional centres of the ribosome, as
it is responsible for peptide bond formation. In addition, the PTC defines
the entrance to the exit tunnel used by nascent peptides on their way
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23J.L. Elson et al. / Mitochondrion 25 (2015) 17–27out of the ribosome. Given its central role it is widely believed that the
PTC is one of the oldest polymeric elements of biological systems. It is
composed of helices H74, H80, H89, H90, and H91–H93 of domain V
(Fig. 1) (Petrov et al., 2014). Not surprisingly, this is the region of the
LSU that contains most of the mutations with the highest disruptive
potential.
The 1253G N A (m.2923G N A) variant was observed as a
homoplasmic variant in a sample of tissue from a prostate cancer
patient (Jeronimo et al., 2001). The canonical 1253G:1066C base pair,
mapping to helix H74, forms tertiary interactions via its major
and minor grooves with positions 1139C and the nearly invariant
1415A of helix H93 (A-minor motif), respectively (bacterial:
(A2598·{C2073:[G2436})·U2245]; Cv(A2598) = 1.913, Cv(C2073) = 1.694,
Cv(G2436) = 1.726, Cv(U2245) = 1.162)CbeamM (Fig. 2E). This interaction
is extended via a double hydrogen bond interaction between 1415A
and the structurally adjacent 1412G of helix H93. A heteroplasmic
G N C base change has been detected at position 1412G (m.3082G)
(bacterial: G2595; Cv(G2595) = 1.957) in a sample from an oesophageal
cancer (Liu et al., 2012). The importance of these interactions is clear,
as they allow the integration of several RNA elements needed to build
the peptidyl transferase region. First, the single stranded stretch joining
helices H75 and H80 interacts with the major groove of H74 via the
aforementioned contacts involving residue 1139C CbeamM. On the
minor groove side of helix H74 contacts are made to the terminal loop
of helix H93 that involves residues 1412G and 1415ACbeamM.
Notably, helices H80 and H93 carry key residues involved in the
correct positioning of the A- and P-site tRNAs at the PTC; as such, it
would be expected that disruption of local structure in this region
could seriously affect ribosomal function. Supporting this view, muta-
tions at the neighbouring 1255U (bacterial: U2438; Cv(U2438) = 1.847)
have been generated in Halobacterium halobium, showing a degree of
disruption that was in agreementwith the predicted level of local struc-
ture distortion (Leviev et al., 1994). Taking all these data together, it
appears reasonable to propose that the 1253G N A (m.2923G N A) and
1412G N C (m.3082G N C) mutations (Jeronimo et al., 2001; Liu et al.,
2012), both resulting in loss of hydrogen bonding potential, should
yield phenotypes that disrupt ribosome function. Given this, we regard
both mitochondrial variants as “likely disruptive”. Additionally, the
universal conservation 1412G was also considered an important factor
in the assignment as “likely disruptive”, as no instances of G N A substi-
tution at this position exist, as determined by Cannone et al. (2002).
7.3.1. P-loop
Two interesting mutations have been mapped to helix H80 whose
capping loop is known as the P-loop. The 1145G N A (m.2815G N A)
variant was found independently in a COX-deficient colonic crypt
(60% heteroplasmy) (Fig. 1) (Taylor et al., 2003) and as a homoplasmic
base change in a COX-deficient urothelium patch (Gaisa et al., 2011). In
addition, a G N A variationwas detected as homoplasmic at the adjacent
residue, 1146G (m.2816G), again in a COX-deficient colonocyte
(Greaves et al., 2010). Mutagenesis studies performed in bacteria have
shown that base changes at the equivalent residues, G2251
(Cv(G2251) = 1.987) and G2252 (CvG2252) = 1.912), and at the adjacent
G2253 (Cv(G2253) = 1.781) are dominant lethal (Samaha et al., 1995;
Lieberman and Dahlberg, 1994; Green et al., 1997). The reason for this
dramatic phenotype is related to the involvement of these residues in
the peptidyl transferase reaction. Specifically, Watson–Crick interaction
between G2252 and G2251 in the so-called P-loop of H80, and positionsFig. 2. Structural analysis of variants with high disruptive potential. A) 173U N C (m.1843T N C).
923G (m.2593G). D) 889U N G (m.2559T N G). E) 1253G N A (m.2923G N A) and 1412G N C
(m.2839C N A). G) 1328U N C (m.2998T N C) and 1398G N A (m.3068G N A). H) 1420G N A (m
(m.3094G N A). J) Secondary-structure diagramwith explanatory boxes indicating the location o
and light green to simplify the visualization of thefigure. Variant sites inA–I are shown inaquam
F, G, H, and I and SSU structure in D were superimposed as described inMethods. Insets corresp
rRNA domains are indicated in insets with Roman numerals. Variant and associated sites in ins
figure legend, the reader is referred to the web version of this article.)C74 and C75 on the acceptor end of P-site tRNA are essential for proper
substrate positioning during peptidyl transfer (Fig. 2F) (Selmer et al.,
2006; Samaha et al., 1995; Green et al., 1997; Nissen et al., 2000;
Feinberg and Joseph, 2006). Since it is expected that mutations at themi-
tochondrial equivalents should result in similar phenotypes, the
1145G N A (m.2815G N A) and 1146G N A (m.2816G N A) variants are
regarded as “expectedly disruptive” (Taylor et al., 2003;Gaisa et al., 2011).
Yet anothermutationmapping to theneighbourhood of the P-loop is
the 1169C N A (m.2839C N A) variant, which has been detected as a
heteroplasmic variant in a patient with Dupuytren's disease (Fig. 1)
(Bayat et al., 2005). Position 1169C canonically base pairs with 1149G
(bacterial: G2255:C2275; Cv(G2255)=1.683; Cv(G2275) = 1.650) bringing
together the P-loop and helix H81 (Fig. 2F). In summary, the location of
the 1169C N A (m.2839C N A) variant in the close neighbourhood of the
functionally important P loop, together with the structurally disruptive
character of the base change makes this mutation a candidate for a
“likely disruptive” mutation.
7.3.2. H90
The 1328U N C (m.2998T N C) variant has been identified as a
heteroplasmic variant in a patient with breast cancer (Fendt et al.,
2011). 1328U is part of a non-canonical pyrimidine–pyrimidine base
pair interaction involving residue 1392U within helix H90Cbeam
(bacterial: U2511·C2575; Cv(U2511) = 1.930, Cv(C2575) = 1.135) (Figs. 1
and 2G). The adjacent residue, 1393G (bacterial: G2576; Cv(G2576) =
1.804) is flipped out of the helix andmodelled in the syn conformation-
CbeamM. This conformation positions 1393G's N1 within hydrogen
bonding distance of the RNA backbone at position 1323UCbeam?, an
almost universally conserved residue (bacterial: U2506; Cv(U2506) =
1.976) that in bacteria has been shown to be directly involved in the
binding of the A-site amino acid at the PTC (Fig. 2G) (Voorhees et al.,
2009). Given this location, it is expected that mutations resulting in
the disruption of local structure could seriously affect peptidyl transfer-
ase and/or tunnel activities. Indeed, mutations at the bacterial equiva-
lent of position 1393G resulted in almost 3-fold increase in growth
rate and conferred resistance to the antibiotic linezolid (Long et al.,
2010). In light of these data, it appears logical to suggest that the
1328U N C (m.2998T N C) variant identified by Fendt et al. (2011) should
be regarded as a “likely disruptive” mutation with potential to cause
linezolid hyper susceptibility. Interestingly, a homoplasmic U insertion
has been detected at the same position in a patient with lung cancer
(Lorenc et al., 2003). Regarding this insertion, it is not clear whether it
might cause enough local distortion to result in peptidyl transferase
defects and/or linezolid hyper susceptibility. As a result, the insertion
variant is considered “NEE”.
We have identified a homoplasmic G N A mutation at the nearly
invariant position 1398G N A (m.3068G N A) in a COX deficient tumour
from a patient with a tubulovillus adenoma of the rectum (bacterial:
G2581; Cv(G2581) = 1.905). 1398G maps to helix H90, where it
is modelled in the syn conformationCbeamM (Figs. 1 and 2G). This
conformation is stabilized by intra-chain hydrogen bonds between
1398's base and the RNA backboneCbeamM and by its stacking between
the universally conserved 1397U (m.3067U)CbeamM (bacterial:
U2580; Cv(U2580) = 2.000) and 1427U (m.3097U) (bacterial: C2610;
Cv(C2610) = 0.991)Cbeam− (Fig. 2G). Particularly important is the role of
neighbouring position 1400G (bacterial: G2583; Cv(G2583) = 1.969),
which in bacteria stabilizes the A-site tRNA in the PTC by forming a
Class I A-minor interaction with position A76 of this tRNA, a residueB) 629U N A (m.2299T N A) and 1010U N C (m.2680T N C). C) 875U N C (m.2545T N C) and
(m.3082G N C). F) 1145G N A (m.2815G N A), 1146G N A (m.2816G N A), and 1169C N A
.3090G N A) and 1409G N A (m.3079G N A). I) 1423C N G (m.3093C N G) and 1424G N A
f the sites ofmutation shown in panels A through I. BoxesG andH are coloured inmagenta
arine, associated sites in red. Ligands and atomic distances are indicated. tRNA structures in
ond to the areas boxed in panel J. Helices are indicated in insets with large grey numbers.
ets are colour coded as on main panel. (For interpretation of the references to color in this
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tack on the peptidyl ester (Voorhees et al., 2009). In agreement with
these observations, mutagenesis experiments have shown that muta-
tions of residues in this region are highly deleterious (Spahn et al.,
1996a,b; Porse et al., 1996). In particular, the G to Amutation at position
2581 conferred a dominant lethal phenotype in E. coli (Spahn et al.,
1996b). Given the COX-deficiency detected in association with the
1398G N A (m.3068G N A) base change, together with its homoplasmic
status, we are prompted to view it as an “expectedly” disruptive muta-
tion. Much like the P loop mutations, the COX-deficiency observed in
the tumour, makes an important case for the consideration of
1398G N A (m.3068G N A) as a proven mutation.
7.3.3. H93
Wehave found a fewvariants in helix H93 that could affect the correct
positioning of tRNAs in the PTC. For example, the 1409G N A
(m.3079G N A) variant was independently identified in samples from
two patients with squamous cell carcinomas (Zhou et al., 2007; Mithani
et al., 2007). This residue base pairs with position 1418C within helix
H93 (bacterial G2592:C2601; Cv(G2592) = 1.923, Cv(C2601) = 1.779)
(Figs. 1 and 2H). Immediately adjacent to this base pair lies another site
of variation, namely 1420G (m.3090G) where a G N A base change has
been identified in a 20-year-old woman with severe myopathy
(Coulbault et al., 2007). The variationwas almost homoplasmic in skeletal
muscle fibres, seen at 50% heteroplasmy in urine; while being absent in
fibroblast, jugal cells, hair follicles, and blood cells (Coulbault et al.,
2007). In the human structure, 1420G base pairs with position 1408C
(bacterial: C2591:G2603; Cv(C2591) = 1.955, Cv(G2603) = 1.967) (Fig. 2H).
Next to 1418C is the almost invariant 1419A (bacterial: A2602;
Cv(A2602) = 1.939), which in bacteria is placed between the acceptor
ends of P- and A-site tRNAs (Voorhees et al., 2009; Selmer et al., 2006).
In agreement with its location, mutations at this residue are dominant le-
thal, arguing for an important role of the residue in the chemical reactions
occurring at the PTC (Polacek et al., 2003; Youngman et al., 2004). In ad-
dition to stabilizing the structure around position 1419A, both 1409G and
1420G mediate contacts between helix H93 and helices H70/H71, thus
linking the peptidyl transferase centre to domain IV of the LSU rRNA.
Given the crucial role of H93 in the chemistry of the PTC, it is expected
that even a small distortion of local structure in this region could have
catastrophic effects on this chemistry. In the case of 1409G N A
(m.3079G N A) and 1420G N A (m.3090G N A), even the potential
formation of wobble base pairs as a result of the G N A base changes
might impose sufficient distortion to result in defective ribosomes. As a
result, the two variations are considered “likely disruptive”.
The 1423C ≥ G (m.3093C N G) and 1424G ≥ A (m.3094G N A) muta-
tionsmap to the proximal end of helix H93 (Figs. 1 and 2I) (Taylor et al.,
2003; Hsieh et al., 2001). 1423C ≥ G (m.3093C N G) was identified in a
patient with MELAS syndrome complicated with diabetes mellitus,
hyperthyroidism and cardiomyopathy (Hsieh et al., 2001), and the
1424G ≥ A (m.3094G N A) variant was detected at level of 40% mtDNA
heteroplasmy in a COX-deficient colonic crypt (Taylor et al., 2003).
In the case of 1423C N G (m.3093C N G), themutationwas present at
51% heteroplasmy in skin fibroblasts of the proband, but at much lower
levels in other tissues and absent in blood. Interestingly, the proband
also carried the inherited MELAS mutation 3243A N G (Hsieh et al.,
2001). The canonical base pair formed by residues 1423C and 1405G
is connected to the reverse Hoogsteen interaction between residues
828U (m.2498U) and 835A (m.2508A) of helix H65 (bacterial:
[U1778·{A1785]·(G2588}:C2606); Cv(U1778) = 1.630, Cv(A1785) = 1.855,
Cv(G2588) = 1.322, Cv(C2606) = 1.004)CbeamM,2 thus contributing to the
packing of domains IV and V of 16S mt-rRNA. Position 1424G stacks
on top of the 1405G:1423C base pair and shares two hydrogen bonds2 Some distances are slightly longer on the Saccharomyces cerevisiae structure. The ar-
chaeal equivalent of position 835A (bacteria: A1785) is C1841. Despite this substitution,
the four-base interaction is maintained in Haloarcula marismortui.with position 883A of helix H65 (bacterial: A1783·G2607; Cv(A1783) =
1.276, Cv(G2607) = 0.967)CbeamM,3 thus mediating the packing of this
helix against H93. High-resolution bacterial structures show that the
equivalents of the neighbouring residues 1400G and 1402U (bacterial:
G2583 and U2585; Cv(G2583) = 1.969, Cv(U2585) = 1.942) are within h-
bonding distance of A76 of A-site tRNA. Not surprisingly, all mutations
at the bacterial position 2585 resulted in dominant lethal phenotypes
(Green et al., 1997). In contrast when a G to C mutation was introduced
at the bacterial equivalent of position 1424G (m.3094G), position
G2607, the authors did not report a pronounced growth defect
(Xu et al., 2005). Additionally, all mutations at the adjacent universally
conserved 1425G (m.3095G) (bacterial G2608; Cv(G2608) = 1.985)
were tolerated without significant effects on the growth of E. coli cells
(Xu et al., 2005). It should be noted that the mutagenesis experiments
of Xu et al. were performed in populations carrying hybrid heteroge-
neous populations of mutant and wild type ribosomes (Xu et al.,
2005); a situation reminiscent of mitochondrial heteroplasmy that
might have obscured any obvious deleterious effects of the mutations
(Xu et al., 2005). This, together with the noted important location of
the base change, prompts us not to dismiss 1424G N A (m.3094G N A)
as a “likely disruptive” mutation. In the case of the 1423C N G
(m.3093C N G) variant, direct biochemical data exists showing impaired
mitochondrial activity in skin fibroblasts from the proband (Hsieh et al.,
2001). Despite these data, the possibility of a nuclearmutation affecting
mitochondrial function has not been clearly ruled out. Taken all the data
together, we consider both 1424G N A (m.3094G N A) and the 1423C NG
(m.3093C N G) as “likely disruptive” mutations. It should be also noted
that resistance to oxazolidinone antibiotics is conferred in bacteria by
mutations at position G2608 (Xu et al., 2005); as such, the possibility
that some type of antibiotic hypersusceptibility might be caused by
the mutations has to be considered.
8. Discussion
The recent publication ofmedium- and near-atomic resolution cryo-
EM structures of themammalianmitoribosome (Brown et al., 2014) has
been used in this report to improve the predictive accuracy of HIA
(Smith et al., 2014; Elson et al., 2015). As a result, we have been able
to analyse the disruptive potential of 64 very rare human variants
mapping to 16S mt-rRNA within their natural structural context. This
work is a significant improvement on our previous report on the muta-
tional landscape of the 12S mt-rRNA, which was performed in the
absence of homologous high-resolution structures (Smith et al., 2014).
However, this new structural knowledge does not decrease the impor-
tance of HIA as a tool for unpicking the role of mt-rRNA mutations in
disease. This is because despite the major advancement brought about
by the achievement of a high-resolution structure of the human mt-
LSU, our knowledge of mitochondrial translation lags far behind our
understanding of this process in heterologous systems. Thus, we have
used in our analysis LSU structures from all three domains of life plus
mitochondria (Table 1) to 1) lessen the effects of potential errors in
the models during our structural assessment, 2) to have a precise
measurement of structural conservation in three dimensions, and
3) to understand the interaction of the human mt-LSU with ligands
during translation. Whenever available, published knowledge gathered
in heterologous systems has been used to refine, support, and provide a
functional rationale to the initial structural analysis. When considering
the importance of HIA in this study, the case of the 173U N C
(m.1843T N C) mutation should be mentioned (Fig. 2A) (Seibel et al.,
2008). The disruptive potential of this mutation can be viewed as
“proven” due to the availability of direct biochemical data performed
in cybrids (Seibel et al., 2008). Despite the obvious relevance of this
mutation, its importance has remained somewhat under appreciated.3 The S. cerevisiae equivalent of 833A (bacterial: A1783) is U2141. As a result, one of the
two hydrogen bonds is lost.
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methods, showing that the same conclusion regarding the effect of
173U N C (m.1843T N C) would be drawn whether or not the human
mt-LSU structure is used for HIA, our analysis has provided a rationale
for its mode of action.
Prior to our work, the only mt-rRNA mutations known to
affect human health were two relatively mild alterations mapping
to SSU mt-rRNA, namely 908A N G (m.1555A N G) and 847C N U
(m.1494C N T) (Bindu and Reddy, 2008; Smith et al., 2014). In addition
to thesemutations, there existed a large number of variants identified in
association to human disease but whose potential pathogenicity was
supported solely by circumstantial evidence. Our previous paper
demonstrated the existence of additional SSU mt-rRNA mutations
identified in the context of human disease and/or ageing with the
capability to interfere and, in some occasions to completely block the
function of the mitoribosomal SSU (Smith et al., 2014). The fact that
the twomitoribosomal subunits have distinct, but complementary func-
tions, made it all themore important to answer the question of whether
the function of the mitoribosomal LSU rRNA can also be compromised
bymutations found associated to human disease and/or ageing. Howev-
er, proof of the involvement of LSU mt-rRNA component in human
disease was yet to be documented, despite the existence of the paper
by Seibel et al. (2008). Hence, our goal was to investigate whether LSU
mt-rRNA mutations exist with the potential to disrupt mitoribosomal
translation. As discussed in our previous paper (Smith et al., 2014), we
confined our search for highly disruptive mutations to a limited to a
subset of very rare base changes. While this practice would likely
leave out some important pathogenic mutations (Smith et al., 2014), it
is the most direct way towards the identification of highly disruptive
mt-rRNA alterations, those likely to play a role in the disease process.
Our results show that, much like in the case of the SSU mt-rRNA, its
larger counterpart in the mitoribosome can harbour highly disruptive
mutations. Such mutations target the main functional centres of the
mitoribosomal LSU such as the PET and the PTC.
One interesting outcome of this study has been the emergence of
structural elements associated with the PET of the mammalian
mitoribosome, as sites often targeted by potentially pathogenic muta-
tions (Table 1). Two PET mutations identified in cancer samples clearly
stand out: the “likely” disruptive 629U N A (m.2299T N A) and the
“expectedly” disruptive mutation identified at position 1010 (m.2680)
(Table 1, Fig. 2B) (Gochhait et al., 2008; Polyak et al., 1998). Besides
these two mutations, eight additional “NEE” mutations map to this
functional element (Table 1), particularly to helix H32, which contains
five such mutations (yellow box in Fig. 1). While some mutations
mapping to the PET have been identified in heterologous organisms
(Kloss et al., 2000; Zaman et al., 2007; Vazquez-Laslop et al., 2008;
Nakatogawa and Ito, 2002; Lucier et al., 1995), this region of the
ribosome has seldom been targeted by mutagenesis analysis. This is
especially true for tunnel-associated regions not adjacent to the PTC,
such as the structurally conserved helix H32. Given this lack of heterol-
ogous evidence, it is not surprising that neither the “likely” nor the “ex-
pectedly” categories of Table 1 are populated with H32 mutations.
Hence, our results highlight the likely functional importance of this
region and prompt for heterologous mutagenesis studies to further
assess its role in ribosomal function.
We would like to emphasize that our predictive methods can, for
certain mutations, unambiguously establish their disruptive potential,
unless a molecular mechanism of translation in mitochondria is
proposed that is completely different from that observed in all other
domains of life. Such a proposal will be in stark contrast to all the
available evidence, particularly with the latest high-resolution
mitoribosomal structures, which have confirmed that the universal
conservation of the ribosomal core is indeed preserved in the mamma-
lian mitoribosome (Brown et al., 2014). For example, the two P-loop
mutations 1145G N A (m.2815G N A) and 1146G N A (m.2816G N A)
(Greaves et al., 2010; Taylor et al., 2003; Gaisa et al., 2011) target twoadjacent residues known to be essential for the recognition and binding
of P-site tRNA (Fig. 2C). Ample biochemical and structural evidence
showing the essential nature of the two elements of this binding
event, namely the CCA terminus of P-site tRNA and the identity of the
equivalents of positions 1145G and 1146G (Samaha et al., 1995; Green
et al., 1997; Monro et al., 1968), leads to the inescapable conclusion
that the two mitochondrial mutations must seriously disrupt the func-
tion of the affected mitoribosomes. A similar case can be made for the
1398G N A (m.3068G N A) base change, known to cause dominant lethal
phenotypes in bacteria, a fact that was in agreement with an important
role of this residue in the stabilization of the A-site tRNA during peptidyl
transfer (Fig. 2D) (Spahn et al., 1996b). Given all this evidence, together
with the homoplasmic status of all three mutations, they can almost
certainly be considered to be the cause of the COXdeficiencies observed
in the original samples (Greaves et al., 2010; Taylor et al., 2003; Gaisa
et al., 2011).
In addition to these mutations, our studies have revealed a number
of “likely” disruptive variants. As initially proposed in our previous
paper (Smith et al., 2014), our work has served to prioritize these
mutants for additional studies such as heterologous mutagenesis
studies that could confirm their suspected disruptive role. One clear ex-
ample is that of 1169C (m.2839C), which is structurally associated to
the P-loop and has been linked to the onset of Dupuytren's disease in
a group of patients (Fig. 2C) (Bayat et al., 2005). In Bayat et al.'s study
(Bayat et al., 2005), 18 out of 20 patients carried the 1169C N A
(m.2839C N A) mutation, suggesting a connection between the
mutation and the symptoms observed in the patients. The tight
structural connection between this “likely” disruptive site and the
functionally crucial P-loop provides a possible functional defect to
explain the symptoms observed by Bayat et al. (2005). It should be
noted, however, that other studies have ruled out the 1169C N A
(m.2839C N A)mutation as the only causative agent of Dupuytren's dis-
ease (Anderson et al., 2012). Much like the case of 1169C N A
(m.2839C N A), the “likely” disruptive 1420G N A (m.3090G N A)
mutation, identified in association with progressive myopathy, is a
strong causal candidate of the observed symptoms (Coulbault et al.,
2007). Position 1420G is adjacent to the almost invariant 1419A
(bacterial: A2602; Cv(A2602) = 1.939), which in bacteria is placed
between the acceptor ends of P- and A-site tRNAs (Fig. 2E) (Voorhees
et al., 2009; Selmer et al., 2006). In both cases, the structural and
functional conservation of the involved regions of the PTC, together
with the key role in translation of neighbouring residues, makes these
sites of mutation obvious targets for heterologous mutagenesis studies
that could confirm their disruptive roles.
Finally, we would like to highlight the case of “likely” disruptive
1423C N G (m.3093C N G). This mutation is particularly interesting due
to its occurrence with the well-known m.3243A N G mutation, which
affects the taurine modification of the wobble position within the
anticodon stem loop of mitochondrial tRNALeu(UUR) and reduces the
translation of UUG codons (Kirino et al., 2004). The authors hinted at the
possibility that the 1423C N G (m.3093C N G) and the m.3243A N Gmu-
tation could act in synergy to cause the symptoms observed in the
proband (Hsieh et al., 2001). Such synergy could occur if the structural
distortion of the PTC, imposed by the 1423C N G (m.3093C N G)
mutation (Fig. 2F), effectively amplified the defect introduced by the
tRNA alteration. Despite the long distance separating the PTC from the
wobble position of tRNA, such an idea would not be too surprising, as
it has been amply demonstrated that mutations affecting the structure
of the PTC of the LSU can effectively alter the fidelity of decoding in
the SSU (Thompson et al., 2001b; O'Connor and Dahlberg, 1995;
O'Connor and Dahlberg, 1993).
In summary, our present and previous results (Smith et al., 2014),
unequivocally expand the number of mt-rRNA mutations associated
with human disease and/or ageing that are capable of severely
compromisingmitoribosomal function. Taking into account that delete-
rious mutations have also been identified in nuclear genes encoding
26 J.L. Elson et al. / Mitochondrion 25 (2015) 17–27protein components of mitoribosomes, mitochondrial translation fac-
tors, and elements of the apparatus involved in the maturation of
mitoribosomes (Miller et al., 2004; Smits et al., 2011; Serre et al.,
1832; Galmiche et al., 2011; Akama et al., 1802; Camara et al., 2011;
Dennerlein et al., 2010; Kolanczyk et al., 2011), our results strongly
complement an emerging view of the mitoribosome as a key element
for human health.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.mito.2015.08.004.
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